NCIt definition : An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic
lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib
binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation
variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling
and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to
the insulin receptor superfamily and plays an important role in nervous system development.
ALK dysregulation and gene rearrangements are associated with a variety of tumor cell
types.;
UNII : K418KG2GET;
InChIKey : VERWOWGGCGHDQE-UHFFFAOYSA-N;
CAS number : 1032900-25-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1032900-25-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;